Adaptimmune Therapeutics plc
ADAP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | -0.00 | 0.03 |
| FCF Yield | -55.06% | -131.52% | -25.66% | -22.58% |
| EV / EBITDA | -3.27 | -1.37 | -1.78 | -15.62 |
| Quality | ||||
| ROIC | -35.07% | -39.82% | -37.82% | -5.87% |
| Gross Margin | 81.71% | 87.93% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.15 | 1.40 | 0.48 | 3.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.75% | 36.15% | 87.18% | 115.31% |
| Free Cash Flow Growth | 47.66% | -88.24% | 35.54% | -217.70% |
| Safety | ||||
| Net Debt / EBITDA | -0.86 | -0.18 | 0.25 | 3.29 |
| Interest Coverage | -31.48 | -24.31 | -42.92 | -13.24 |
| Efficiency | ||||
| Inventory Turnover | 0.22 | 0.07 | 0.00 | 0.00 |
| Cash Conversion Cycle | 261.86 | 877.88 | 446.42 | 84.97 |